Compare Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Russell 2000 0DTE Covered Call Strat ETF vs Recursion Pharmaceuticals Inc — how do they compare? Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $27.35, while Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B). Which is the better fit depends on your goals.
| RDTE | RXRX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $34.10 | $6.79 |
52-Week Low | $26.40 | $2.84 |
Market Cap | — | $1.86B |
Enterprise Value | — | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RDTE trades at $27.84, down 0.32% with a bearish technical outlook showing 16 sell signals versus 3 buy signals. The ETF maintains an aggressive dividend distribution strategy with multiple payments in 2026, though key valuation metrics remain unavailable for analysis. Technical indicators show oversold conditions with RSI at 27.52 but strong bearish momentum from moving averages.
The outlook remains cautious due to structural capital erosion risks identified by analysts. While the high dividend yield near 39% attracts income investors, the covered call strategy caps upside potential and exposes investors to full downside risk. Recent analyst reports highlight concerns about NAV deterioration and failure to capture index rallies.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
